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Resumo
Objetivo: O transplante pâncreas-rim é efe-
tivo para pacientes com doença renal crô-
nica terminal e diabetes mellitus insulino-
dependente. A função retardada do enxerto 
pancreático é condição frequente exercendo 
impacto significativo nos resultados em cur-
to prazo dos transplantes pâncreas-rim. O 
objetivo foi analisar o impacto da função 
retardada do enxerto pancreático no trans-
plante pâncreas-rim. Métodos: Análise re-
trospectiva de 180 receptores de transplante 
pâncreas-rim, incluindo dados demográfi-
cos dos doadores e dos receptores, a reati-
vidade contra painel, a incidência de rejei-
ção aguda e as sobrevidas do paciente e dos 
enxertos pancreático e renal. Resultados: A 
incidência de função retardada do enxerto 
pancreático foi 11%. A idade do receptor 
superior a 45 anos apresentou associação 
com o risco de desenvolvimento de função 
retardada do enxerto pancreático (Razão de 
chances 2,26; p < 0,05). Os pacientes com 
função retardada do enxerto pancreático 
apresentaram maior incidência de rejeição 
aguda renal (47 versus 24%; p < 0,05), gli-
cemia de jejum alterada (25 versus 5%; p < 
0,05) e média de hemoglobina glicada (5,8 
versus 5,4%; p < 0,05) ao final do primei-
ro ano de acompanhamento em relação aos 
pacientes sem função retardada do enxerto 
pancreático. Não houve diferenças estatis-
ticamente significativas entre os grupos de 
pacientes com e sem função retardada do 
enxerto pancreático quanto à sobrevida do 
paciente (95 versus 88,7%; p = 0,38), do 
enxerto pancreático (90 versus 85,6%; p = 
0,59) e do enxerto renal (90 versus 87,2%; 
p = 0,70), respectivamente, nesse mesmo 
período. Conclusão: A função retardada 
do enxerto pancreático não exerceu im-
pacto significativo nos resultados em curto 
prazo dos transplantes pâncreas-rim desta 
AbstRAct
Objective: Simultaneous pancreas-kidney 
transplantation is an effective treatment 
for patients with type 1 diabetes melli-
tus and end-stage chronic kidney disea-
se. Delayed pancreatic graft function is a 
common and multifactor condition with 
significant impact in short-term outcome 
of simultaneous pancreas-kidney trans-
plantations. The aim of this study was to 
analyze the impact of pancreatic delayed 
pancreatic graft function on simulta-
neous pancreas-kidney transplantation. 
Methods: Donor and recipient’s demo-
graphic data, percentage of panel reacti-
vity, acute rejection incidence, and patient 
and grafts survivals were retrospectively 
analyzed in 180 SPKT performed betwe-
en 2002 and 2007. Results: The inciden-
ce of pancreatic delayed pancreatic graft 
function was 11%. Donors older than 45 
years had significant risk of pancreatic de-
layed pancreatic graft function (OR 2.26; 
p < 0,05). Patients with pancreatic delayed 
pancreatic graft function had higher rates 
of acute renal rejection (47 versus 24%; p 
< 0.05), altered fasting plasma glucose (25 
versus 5%; p < 0.05) and mean glycated 
hemoglobin (5.8 versus 5.4%; p < 0.05), 
than patients without pancreatic delayed 
pancreatic graft function at the end of the 
first year of follow up. There were no sig-
nificant differences between patients with 
and without pancreatic delayed pancrea-
tic graft function regarding patient survi-
val (95 versus 88.7%; p = 0.38), pancre-
atic graft survival (90 versus 85.6%; p = 
0.59) and renal graft survival (90 versus 
87.2%; p = 0.70), respectively at the sam-
ple period of time. Conclusion: Pancreatic 
delayed pancreatic graft function had no 
significant impact in the short-term ou-
tcome of simultaneous pancreas-kidney 
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IntRoductIon
Simultaneous pancreas-kidney transplantation 
(SPKT) is a therapeutic modality accepted throu-
ghout the world for insulin-dependent patients with 
type 1 diabetes mellitus (DM) and end-stage chro-
nic kidney disease, especially when they also pre-
sent inappropriate glycemic control, asymptomatic 
hypoglycemia, and lesions in target organs. SPKT is 
not formally recommended for patients with type 2 
diabetes.1
In the United States, survival rates of patients sub-
mitted to SPKT after 1 and 5 years of follow-up are 
95% and 87%, respectively. Survival rates of pancre-
atic graft after 1 and 5 years are 84% and 73%, res-
pectively, and survival rates of renal graft after 1 and 
5 years are 92% and 78%, respectively.2 In Brazil, 
according to the Brazilian Transplantation Registry, 
survival rates of patients submitted to SPKT after 1 
and 5 years are 83% and 77.3%, respectively.3
 The benefits of SPKT are not limited to glycemic 
control and treatment of end-stage uremia; it also im-
proves the disabling comorbidities related to long-las-
ting diabetes mellitus. In most patients, retinopathy 
related to DM estabilizes.4 In addition, a significant 
reduction in the occurrence of cardiovascular episo-
des in the long term follow-up is often observed, as 
well as improvement in markers of atherosclerosis of 
coronary circulation and of performance of the left 
ventricle.5-7
Delayed pancreas graft function (DPGF) is a signi-
ficant risk factor for the survival of renal and pancre-
atic grafts, and also for the patient. DPGF is the result 
of a combination of factors related to the recipient, 
the donor, and also to ones inherent to the transplant 
itself. Although the absence of standardized diagnos-
tic criteria makes analysis and comparison of results 
more difficult among different centers, DPGF has be-
en strongly associated with a poorer prognosis after 
SPKT.8-10
This study aims at analyzing the results of the 
SPKT performed at Universidade Federal de São 
Paulo (Unifesp); the incidence and risk factors for the 
occurrence of DPGF; and the impact of DPGF on the 
short-term survival rates of patients and renal and 
pancreatic grafts.
methods
One hundred and eighty medical records of SPKT 
recipients who were subjected to surgery between 
December 2000 and September 2007 at Unifesp we-
re analyzed. The research project was previously ap-
proved by the Research Ethics Committee of Unifesp 
(protocol No 162/08). 
indicatiOns and surgical techniques
SPKT was indicated for insulin-dependent diabetic 
patients who were not obese [body mass index (BMI) 
<32 kg/m²], aged no more than 55 years old, presen-
ting instability in glycemic control and two or more 
complications related to DM, such as nephropathy, 
retinopathy, and neuropathy.
The first 41 transplantations were performed wi-
th grafts obtained from donors who had been expo-
sed to 2 L of Belzer solution, for the perfusion of the 
aorta before organ removal. As to the remaining do-
nors, different combinations of solutions were used: 
Belzer, Euro-collins, Celsior, and histidine-tryp-
tophan-ketoglutarate. Renal graft was preferably 
placed into the left iliac fossa, by the standardized 
surgical technique of kidney transplant, with termi-
no-lateral vascular anastomosis in the external iliac 
vessels and urethrovesical anastomosis, especially 
with the Gregoir technique. Pancreatic transplan-
tation was performed after the kidney transplant, 
whenever the cold ischemia time of the pancreatic 
graft was less than 10 hours.11 Pancreatic graft was 
inserted in the right iliac fossa with termino-lateral 
anastomosis in the external iliac vessels. Surgical 
casuística. Embora a função retardada do enxerto pan-
creático não tenha influenciado a sobrevida do enxerto 
pancreático ao final do primeiro ano após o transplante, 
contribuiu para a disfunção pancreática precoce, indi-
cando maior necessidade de uso de insulina e hipoglice-
miantes orais.
Palavras-chave: Transplante de rim. Transplante de 
pâncreas. Rejeição de enxerto. Análise de sobrevida. 
Modelos logísticos.
transplantations. Although delayed pancreatic graft 
function had no impact on 1-year pancreas graft sur-
vival, it contributed to early pancreas graft dysfunc-
tion, as assessed by enhanced insulin and oral anti-
diabetic drugs requirements.
Keywords: Kidney transplantation. Pancreas trans-
plantation. Graft rejection. Survival analysis. Logistic 
models.
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techniques included exocrine bladder derivation in 
the first seven transplantations, and exocrine enteric 
derivation in the others. Bladder exocrine derivation 
was early renounced due to the high frequency of 
unfavorable evolution with dehydration, hemorrha-
gic cystitis, and pancreatic reflux. 
immunOsuppressiOn
All patients received a combination of calcineurin 
inhibitor, prednisone, and mycophenolate. The cal-
cineurin inhibitor used in the first 16 patients was 
cyclosporine, at a dosage of 5-6 mg/kg twice a day. 
The initial cyclosporine dose was adjusted in or-
der to obtain blood concentration between 150 and 
200 ng/ml (up to 30 days), 100 and 150 ng/ml (30 
to 90 days), and 50 and 100 ng/ml (> 90 days). 
The calcineurin inhibitor used in the other patients 
was tacrolimus, at a dosage of 0.15 mg/kg twice a 
day. The dose of tacrolimus was adjusted in order 
to obtain blood concentration between 10 and 15 
ng/ml (up to 30 days),  8 and 12 ng/ml (30 to 90 
days), and 5 and 10 (> 90 days). Prednisone was 
used at an initial dosage of 0.5 mg/kg, with a ma-
ximum daily dose of 30 mg/day, and a progressive 
reduction every 3 weeks, until 5 mg/day 180 days 
after transplantation. Transplant recipients who 
were subjected to surgery before January 31, 2005 
received mycophenolate mofetil at a dosage of 1.0 
g twice a day. After this date, the recipients were 
given the formulation of mycophenolate sodium at 
a dosage of 720 mg twice a day. Therapy with mo-
no- or polyclonal antilymphocyte antibodies was 
reserved for the recipients who presented elevated 
risk of delayed renal graft function, for patients 
who had previously been submitted to transplan-
tations or for those who were hypersensitive (reac-
tion against a panel of cells superior to 30%). Some 
of the recipients who did not meet the described 
criteria indicating treatment with antilymphocyte 
antibodies received anti-IL-2R antibodies after July 
30, 2003.
study design and data cOllectiOn
The selection of patients and the data collection 
were conducted retrospectively. At first, the analy-
sis focused on demographic and clinical characte-
ristics, incidence of acute renal and pancreatic re-
jection, short-term survival of patients and renal 
and pancreatic grafts. There was a suspicion of epi-
sodes of acute rejection, considering both renal and 
pancreatic grafts, based on clinical, laboratorial, 
ultrasonographic, and histological findings. The 
study considered as acute renal and pancreatic re-
jection all the episodes treated for at least three 
days, with or without histological confirmation. 
Increase in serum amylase and lipase, as well as 
sudden hyperglycemia, were considered as criteria 
for indication of pancreatic graft biopsy. The 180 
patients were analyzed in two distinct subgroups, 
according to the presence of DPGF. DPGF was de-
fined as the need for insulin at the time of hospital 
discharge.10 Delayed renal graft function was de-
fined as the need for dialysis during the first we-
ek post-transplant. As secondary end-points, the 
incidence of post-transplant DM, alterations of 
fasting glucose (between 100 and 125 mg/dl), deep 
venous thrombosis, pancreatic fistulas, peripancre-
atic abscesses, pancreatitis and dyslipidemia were 
analyzed, as well as the levels of serum glycated he-
moglobin, renal function estimated by the formula 
of MDRD12, and BMI at the end of the first year 
of follow-up in both groups. Data collection was 
based on medical records. September 30, 2008, was 
the due date for the registration of events and for 
the calculation of follow-up time.
The analyzed variables were age, gender, pre-
transplant BMI, time of DM diagnosis, type of re-
nal replacement therapy, cold ischemia time of renal 
graft, cold ischemia time of pancreatic graft, reac-
tion against a panel of cells, and post-transplant 
time of hospitalization. Donor’s age and BMI were 
also assessed. 
statistical analysis
Data were presented by absolute frequency, as well 
as percentage, means, standard deviation, and ma-
ximum and minimum values whenever it was ap-
propriate. The chi-square test was used to compa-
re categorical variables. Student’s t-test was used 
to compare continuous variables. Kaplan-Meier 
was used for univariate analysis of both patient 
and graft survival. Log-Rank method was used to 
compare survival curves of patients who did or did 
not have DPGF. The contribution of the variables 
“recipient’s age”, “donor’s age”, “donor’s BMI”, 
“recipient’s BMI”, “time of diabetes diagnosis”, 
“percentage of reaction against a panel of cells”, 
“donor’s death due to cardiovascular problems”, 
and “cold ischemia time of pancreatic graft over 
the risk of DPGF” was analyzed through multiple 
logistic regression analysis. The results were pre-
sented according to odds ratio index. The value p < 
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0.05 was considered statistically significant. All sta-
tistical analysis was conducted with the Statistical 
Package for the Social Sciences (SPSS) program.
Results
patients
Demographic characteristics of the 180 patients (re-
cipients and donors) classified according to the pre-
sence of DPGF are shown in Table 1. There were no 
statistically significant differences as to age, gender, 
pre-transplant BMI, time of diabetes diagnosis, type 
of renal replacement therapy, cold ischemia time of 
pancreatic and renal grafts, reaction against a panel 
of cells, time of hospitalization, use of immunosup-
pressants with mono- or polyclonal antilymphocyte 
antibodies, and use of immunosuppressants with 
anti-IL-2R in the group of recipients that evolved 
with DPGF (n = 19) and the group without DPGF 
(n = 161). Also, there were no statistically signi-
ficant differences in the groups as to age, donor’s 
BMI and use of different preservation solutions.
rates Of acute rejectiOn
In the end of the first year of follow-up, 49 pa-
tients had rejected renal graft (27%) and 12 had 
rejected pancreatic graft (6%). Patients that de-
veloped DPGF had an incidence of renal acute re-
jection significantly higher than the ones who did 
not have DPGF (47% versus 24%, respectively, p 
<0.05). There was no significant difference in the 
incidence of DRGF between the groups (21 versus 
24, p=0.71). However, no statistically significant 
table 1. transplant recipient and dOnOr demOgraphic data
*Other solutions included different combination of Belzer, Euro-collins, Celsior, and Histidine-Tryptophan-Ketoglutarate 
solutions.
Variable DPGf absence n = 161 DPGf presence n = 19 p value
    
Recipient    
Age (years) 35 (17-55) 39 (22-57) 0.082
Female 48% 55% 0.571
BMI (kg/m2) 21.2 (15.8-36.9) 21.1 (16.9-37.4) 0.459
Time of DM (years) 21 (10-37) 22 (6-43) 0.560
Renal Replacement Therapy   0.632
Hemodialysis 82% 75%  
Peritoneal dialysis 13% 25%  
Conservative treatment 6% 0%  
renal CIT (hours) 14 (6-29) 14.5 (6-26) 0.602
pancreatic CIT (hours) 14 (5-27) 14.5 (8-23) 0.450
Reactivity against a panel of cells> 30% 3% 5% 0.489
Hospitalization (days) 21.9 ± 26 20.8 ± 2.2 0.850
Induction with antilymphocytes 
antibodies
11% 15% 0.610
Induction with anti-IL-2R 3.7% 5.2% 0.740
    
Donor    
Age (years) 22 (10-46) 25 (12-44) 0.161
BMI (kg/m2) 23.4 (12.5-42.2) 23.8 (15.4-31.2) 0.854
Preservation Solutions   0.100
Belzer 1L + Belzer 1L 55% 47%  
Eurocollins 1L + Belzer 1L 26% 21%  
Others* 13% 31%  
No information 4.3% -  
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differences were observed between the rates of pan-
creatic acute rejection in the group of patients with 
DPGF in comparison with the group without DPGF 
(15% versus 5%, p = 0.1) (Figure 1). According 
to the post-transplant time, ten were considered as 
early rejection (in the first 30 days of follow-up) 
and two were considered as late rejection (after 6 
months of follow-up). Considering only the 10 pa-
tients who presented early rejection, 3 (30%) also 
had DPGF. Minimum time of hospital stay was 8 
days, and maximum was 28 days (14 ± 6.5 days).
cOmplicatiOns
The proportion of patients with DPGF who had 
diabetes in the end of the first year of follow-up 
was not significantly different from the proportion 
of patients without DPGF who had diabetes (11% 
versus 2%, respectively, p = 0.08). However, when 
the patients who had diabetes (diagnosed after 
transplantation) were excluded from the sample, 
it was observed that the number of patients who 
presented altered fasting glycemia was percentually 
higher in the group with DPGF (25% versus 5%, p 
= 0.02), as well as the glycated hemoglobin means 
(5.8% versus 5.4%, p < 0.05). Patients who develo-
ped DPGF also received insulin (26.3% versus 2%, 
p < 0.05) and oral hypoglycemic drugs (33% ver-
sus 6%, p < 0.05) more frequently than the group 
without DPGF. Considering the 180 patients, 158, 
155, 159, and 171 did not need insulin until the end 
of 1, 3, 6, and 12 months of follow-up, respectively. 
Among the 19 patients who developed DPGF, 12, 
11, 9, and 5 received insulin until the end of 1, 3, 6, 
and 12 months of follow-up, respectively.
The rates of deep venous thrombosis (5% versus 
1%, p = 0.33), pancreatic fistulas (5% versus 10%, 
p = 0.69), peripancreatic abscesses (0% versus 8%, 
p = 0.36), pancreatitis (0% versus 3%, p = 1), dis-
lypidemia (60% versus 52%, p = 0.51), glomerular 
filtration rate estimated by the formula of MDRD (64 
versus 69 mL/min/1.73m², p = 0.33) and BMI values 
evaluated in the end of the first year of follow-up (22 
versus 21.9 kg/m², p = 0.96) were not statistically 
different, respectively, between patients with and wi-
thout DPGF.
survival rates analysis
Survival rates of patients 6 and 12 months after 
transplantation were 86.1% and 83.3%, respecti-
vely. Survival rates of renal graft 6 and 12 months 
after transplantation, including all failures, were 
85% and 81.7%, respectively. Survival rates of 
pancreatic graft 6 and 12 months after transplanta-
tion, including all failures, were 80.3% and 77%, 
respectively.
Survival rates of patients who developed DPGF 
6 and 12 months after transplantation were 100% 
and 95%, respectively, and those of patients who 
did not develop DPGF were 91.5% and 88.7%, 
respectively. Comparison between groups showed 
no statistically significant differences (p = 0.38) 
(Figure 2).
Renal graft survival rates 6 and 12 months after 
transplantation in the group of patients who develo-
ped DPGF, including all failures, were 95% and 90%, 
respectively, and in the group of patients who did 
not develop DPGF, 90.8% and 87.2%, respectively. 
Figure 1. incidence of renal and pancreatic grafts 
acute rejection according to the existence of delayed 
pancreatic graft function. *p < 0,05
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Figure 2. Patients’ survival curve in recipients that 
evolved with or without delayed pancreatic graft 
function.
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Comparison between groups showed no statistically 
significant differences (p = 0.70) (Figure 3).
Pancreatic graft survival rates 6 and 12 months 
after transplantation in the group of patients who 
developed DPGF, including all failures, were 95% 
and 90%, respectively, and in the group of patients 
without DPGF, 89.2% and 85.6%, respectively. 
Comparison between groups showed no statistically 
significant differences (p = 0.59) (Figure 4).
risk factOrs fOr dpgf
Multiple logistic regression analysis indicated that on-
ly the variable “recipient’s age over 45” (odds ratio 
of 2.26, p < 0.05) was identified as a risk factor for 
DPGF. Logistic regression analysis did not show sig-
nificant correlations between the variables: recipient’s 
age over 40 (p = 0.7); donor’s age over 40 (p = 0.08); 
donor’s age over 45 (p = 1); recipient’s BMI higher than 
30 (p = 0.34); donor’s BMI higher than 25 (p = 0.36); 
donor’s BMI higher than 30 (p = 0.9); recipient’s BMI 
higher than 30; and donor’s BMI higher than 25 (p = 
1); time of diabetes diagnosis (p = 0.6); percentage of 
reactivity against a panel of HLA class I cells higher 
than 10% (p = 0.9); percentage of reactivity against 
a panel of HLA class I cells higher than 20% (p = 1); 
percentage of reactivity against a panel of HLA class 
II cells higher than 10% (p = 1); percentage of reacti-
vity against a panel of HLA class II higher than 20% 
(p = 1); donor’s death due to cardiovascular causes (p 
= 0.7) and cold ischemia time of pancreatic graft (0.9) 
over the risk of DPGF development.
dIscussIon
The definition of DRGF that takes into account the 
need for dialysis during the first week of follow-up 
after kidney transplant is adopted by most centers. 
However, diagnosis criteria for DPGF are not widely 
accepted. A great variety of factors related to the cli-
nical conditions of donor and recipient, as well as the 
transplantation itself, significantly influences DPGF 
and contributes to the non-existence of a universally 
accepted definition of DPGF. A proposal for diagnos-
tic standardization included the need for cumulative 
doses of insulin, higher than 30 UI, from 5 to 10 days 
after a successful SPKT, or a higher than 15 UI, be-
tween the 11th and 15th days.8 Another proposal esta-
blished that the need for insulin at hospital discharge 
after a successful pancreas-kidney transplantation 
should be used as an isolated criteria.10 More recently, 
DPGF has been defined as the need for insulin or oral 
hypoglycemic medication and/ or fasting glycemic le-
vel higher than or equal to 126 mg/dl in the first 30 
days post-transplant.9 In the present study, DPGF has 
been defined as the need for insulin at hospital dis-
charge after a successful SPKT according to the crite-
ria proposed by Tan et al. in 2004.10
It is important to mention that the DPGF diagno-
sis according to the criteria used in this study does 
not distinguish functional damage and tissue dama-
ge to the pancreatic graft. Some situations, such as 
recipient’s obesity and lipid disorders, are followed 
by a greater incidence of DPGF due to increased risk 
of resistance to insulin.13 Other factors, such as the 
use of steroids and calcineurin inhibitors, as well as 
Figure 3. Survival curve of renal graft in recipients 
that evolved with or without delayed pancreatic graft 
function, including all losses.  
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Figure 4. Pancreatic survival rates curve, including all 
losses, in recipients who progressed with or without 
delayed pancreatic graft function.
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infections, make the initial function of the pancreas 
more difficult, since they delay tissue regeneration, 
which is necessary after ischemia and reperfusion,14 
and favor the development of ischemia and systemic 
inflamation.8,10 Therefore, glucose intolerance may be 
present without necessarily indicating DPGF seconda-
ry to structural damage. These conceptual differences 
represent additional challenges to establish the role of 
DPGF in the short- and long-term results of SPK.
Many variables are indicated as predisposing fac-
tors for DPGF, such as: donor’s and recipient’s age, 
donor’s and recipient’s BMI, cold ischemia time of 
pancreatic and renal grafts, as well as reactivity against 
a panel of class I and II cells higher than 30%.8,10,15 
Donor’s age over 45 years is pointed out as the main 
risk factor for DPGF,8,10 probably due to the little 
amount of functional pancreatic mass and the pre-
sence of atherosclerotic lesions in the grafts obtained 
from these donors.16 In this study, only the recipient’s 
age over 45 years presented a statistically significant 
association with the development of DPGF.
Glucose tolerance decreases with aging, and it is 
often associated with resistance to insuline.17 Even 
though higher resistance to insulin may be a very 
probable hypothesis to support such observation, 
the impossibility to measure C-peptide during the 
follow-up of these patients did not allow us to esta-
blish definite conclusions. The cause of death of the 
donor has been investigated in some centers as an 
independent risk factor for DPGF. The main eviden-
ce lies on cardiovascular causes, condition in which 
the quality of the organ to be transplanted is much 
inferior.8 The cause of death of the donor was also 
analyzed in this study, and no direct relation between 
the cause of death and the incidence of DPGF was 
found. DM time showed no associations with DPGF 
in this study or preceding ones.8
The adequate preservation of the pancreas is essen-
tial to prevent the development of DPGF. The search 
for more favorable cost-benefit alternatives in compa-
rison to the very expensive Belzer solution, which is 
traditionally the best option for preserving the pancre-
as for transplantation, resulted in the use of different 
combinations of preservation solutions in the donors 
included in the present study.18 Although it may be va-
lid to question the influence of such heterogeneity in 
the results presented in this study, percentage compa-
risons involving the use of different combinations of 
preservation solutions in these groups of patients had 
no statistically significant differences, suggesting that 
different methods of organ preservation did not have 
significant influence on the development of DPGF.
A higher incidence of renal acute rejection among 
the recipients who developed DPGF was observed. 
However, there was no significant difference between 
the groups as to the rate of pancreatic acute rejection. 
Although some methodological variations related to 
the confirmation of diagnosis in acute rejection – both 
for pancreatic and renal grafts –, could explain such 
observations, it is very likely that intravenous steroids 
usually used for the treatment of renal acute rejec-
tion contributed to the post-transplant development 
of DPGF. However, the influence of such variable was 
not specifically investigated in the present study.
Patients with DPGF had severe post-transplant 
dislypidemia (in the first 6 months) more often than 
patients without DPGF.8,9 The cohort of patients 
presented here did not reproduce such observation. 
Severe dislypidemia before SPKT is also described as 
an independent risk factor for DPGF.
Pancreas with fat deposits and several atheroscle-
rotic lesions, usually calcified, presents a higher risk 
of post-transplant technical and metabolic complica-
tions, which indicates that the organ should be discar-
ded under such conditions.19
Family history of DM in first-degree relatives was 
not identified as a significant risk factor for DPGF in 
this study, although some authors have observed that 
SPKT recipients who had first-degree relatives with 
diabetes presented higher levels of insulin secretion 
followed by reduced tissue sensitivity.20,21
It is widely accepted that pancreatic acute rejec-
tion determines dysfunction and immediate pancrea-
tic tissue damage, which is often irreversible and has 
a negative interference on pancreatic graft survival.10 
In addition, there is a strong correlation between pan-
creatic acute rejection and DPGF.8,10 In the present 
study, pancreatic acute rejection had no statistically 
significant association with the occurrence of DPGF. 
Although this observation does not reproduce results 
of previous studies which included a large series of 
patients,9 it is possible that the improvement in the 
diagnosis of pancreatic rejection and the inclusion of 
more patients indicate the expected correlation be-
tween these variables in further analyses.
The main limitations of this study were related to 
the relatively small number of patients, retrospective 
design, and absence of diagnostic uniformity of pan-
creatic acute rejection. Monitoring of amylase and 
lipase serum levels was not systematically used for 
the follow-up of SPKT recipients and not all episo-
des of acute rejection were histologically confirmed. 
Such observations may justify the lower rates of renal 
(27%) and pancreatic (6%) acute rejection compared 
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to multicenter registrations. When considering the 
4,251 recipients of simultaneous pancreas-kidney 
transplantation notified in the North American regis-
tration UNOS, 36% presented at least one episode of 
renal acute rejection, 3% had at least one episode of 
pancreatic rejection, and 16% presented rejection in 
both grafts simultaneously.22
DPGF is significantly associated with lower pan-
creatic survival rates,8 especially when there is an acti-
vation of the immune system, reduced pancreatic mass 
(in older donors), as well as ischemia and reperfusion 
lesions.8 Episodes of intra-abdominal infections, vas-
cular thrombosis and renal acute rejection are also 
known as factors related to lower pancreatic survival 
rates in the short-term (1 year of follow-up).23 The 
presence of DPGF was not a significant risk factor 
for lower survival rates of patients and grafts in the 
present study.
The increase in the use of insulin and oral hypo-
glycemic medication at the end of the first year of 
follow-up after SPK in patients who developed DPGF 
in relation to the group without DPGF indicates par-
tial functioning of the pancreatic graft. Higher glyca-
ted hemoglobin levels were observed after one year 
in patients with DPGF, which may indicate a higher 
incidence of pancreatic graft dysfunction.
Therefore, DPGF determined a greater need for 
oral hypoglycemic medication and insulin during the 
first year of follow-up after SPK, without compromi-
sing patient’s short-term survival, as well as renal and 
pancreatic rates.
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